Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.45%
#2 Venom Venom +25.04%
#3 aelf aelf +15.77%
#4 Decred Decred +10.08%
#5 Status Status +6.67%
#6 Audiera Audiera +6.32%
#7 Wibx Wibx +5.97%
#8 SkyAI SkyAI +5.88%
#9 MarsCoin MarsCoin +5.10%
#10 Talus Network Talus Network +4.84%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Settings
Language
ENGLISH
Currency
USD
Theme
LexaGene Holdings Inc. LexaGene Holdings Inc.

LexaGene Holdings Inc.

0V43
Rank in Stocks #30876
LexaGene Holdings Inc. is a biotechnology firm specializing in the invention,... LexaGene Holdings Inc. is a biotechnology firm specializing in the invention, refinement, and commercialization of systems for detecting pathogens. The company's flagship product, MiQLab, is an automated pathogen identification system engineered to revolutionize diagnostics in diverse sectors, including animal and human healthcare, food and water quality assurance, and other life science applications. This advanced platform functions directly at the location of sample collection, providing remarkable simplicity, heightened sensitivity, and extensive pathogen screening capabilities. Founded in 2007, LexaGene is headquartered in Beverly, Massachusetts.
Share Price
$0.1174299
Last synced: 2023-02-22
Market Cap
$15.21M
Change (1 day)
-0.92%
Change (1 year)
0.00%
Country
US
Trade LexaGene Holdings Inc. (0V43)

Category

Healthcare
Revenue for LexaGene Holdings Inc. (0V43)
Revenue in Aug 2026 TTM: 0
According to LexaGene Holdings Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for LexaGene Holdings Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE